

August 24, 2022 08:46 PM GMT

Vintage Values | North America

Vintage Values 2023

Vintage Values 2023 assembles the best insights of Morgan Stanley Research for stocks to hold for 12 months: mid- to large-caps likely to realize superior risk-adjusted returns over the next year.

For 'Vintage Values 2023', our 13th annual iteration in the series, Morgan Stanley Research's Stock Selection Committee (SSC) wove together fundamental and quantitative analyses to identify our top ideas.

We began by asking each of our North America analysts for their top recommendation for a one-year buy-and-hold investment horizon; more than 50 names were suggested by our analysts. The SSC, in conjunction with our US Equity Strategy team, considered each of these companies' macro exposure, industry positioning, valuation, and, crucially, the risk-reward profile, paying particular attention to the skew of the analysts' Bull- and Bear-Case valuation estimates.

The SSC also considered each stock's ranking within our Quantitative Equity Strategy team's Quality Score. Further, our Global Sustainability Research team worked with the SSC to integrate Environmental, Social, and Governance (ESG) analysis into the selection process.

In evaluating the makeup of the *Vintage Values* list, the SSC also considered the sector weighting recommendations of our US Equity Strategy team, led by Chief Strategist Michael Wilson.

Our 'Vintage Values 2022' list produced a -4.64% return over the period from August 20, 2021 to August 23, 2022, outperforming the S&P 500 by 100 basis points over that time frame. (See inside for more detail regarding *Vintage Values 2022*, as well as important disclosures).

| | |
|----------------------------|---------------------------------|
| Amazon.com | Monster Beverage |
| CBOE Global Markets | Palo Alto Networks |
| CDW Corp. | Simon Property |
| Eli Lilly & Co. | State Street Corp. |
| Endeavor Group | Thermo Fisher Scientific |
| Exxon Mobil | Visa |
| Ferrari | Zoetis |
| Lockheed Martin | |

MORGAN STANLEY & CO. LLC

Michelle M. Weaver, CFA

EQUITY STRATEGIST

Michelle.M.Weaver@morganstanley.com

+1 212 296-5254

Michael J Wilson

EQUITY STRATEGIST

M.Wilson@morganstanley.com

+1 212 761-2532

Andrew B Pauker

EQUITY STRATEGIST

Andrew.Pauker@morganstanley.com

+1 212 761-1330

Diane Ding, Ph.D.

QUANTITATIVE STRATEGIST

Qian.Ding@morganstanley.com

+1 212 761-6758

Nicholas Lentini, CFA

RESEARCH ASSOCIATE

Nick.Lentini@morganstanley.com

+1 212 761-5863

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

Additional Contributors

Morgan Stanley & Co. LLC

Michael Cyprys, Equity Analyst (Brokers & Asset Managers)
(212) 761 7619 / Michael.Cyprys@morganstanley.com

James Faucette, Equity Analyst (Payments and Processing)
(212) 296 5771 / James.Faucette@morganstanley.com

Terence Flynn, Equity Analyst (Major Pharmaceuticals)
(212) 761 2230 / Terence.Flynn@morganstanley.com

Hamza Fodderwala, Equity Analyst (Software)
(212) 761 1083 / Hamza.Fodderwala@morganstanley.com

Betsy Graseck, Equity Analyst (Large Cap Banks & Consumer Finance)
(212) 761 8473 / Betsy.Graseck@morganstanley.com

Richard Hill, Equity Analyst (Real Estate Investment Trusts)
(212) 761 9840 / Richard.Hill1@morganstanley.com

Adam Jonas, Equity Analyst (Autos & Shared Mobility)
(212) 761 1726 / Adam.Jonas@morganstanley.com

Kristine Liwag, Equity Analyst (Aerospace & Defense)
(212) 761 2980 / Kristine.Liwag@morganstanley.com

Devin McDermott, Equity Analyst (Integrated Energy)
(212) 761 1125 / Devin.McDermott@morganstanley.com

Dara Mohsenian, Equity Analyst (Beverages)
(212) 761 6575 / Dara.Mohsenian@morganstanley.com

Brian Nowak, Equity Analyst (Internet)
(212) 761 3365 / Brian.Nowak@morganstanley.com

Tejas Savant, Equity Analyst (Life Science Tools & Diagnostics)
(212) 761 1955 / Tejas.Savant@morganstanley.com

Benjamin Swinburne, Equity Analyst (Media & Entertainment)
(212) 761 7527 / Benjamin.Swinburne@morganstanley.com

Erik Woodring, Equity Analyst (IT Hardware)
(212) 296 8083 / Erik.Woodring@morganstanley.com

Erin Wright, Equity Analyst (Specialty Pharmaceuticals)
(212) 761 6137 / Erin.Wright1@morganstanley.com

Vintage Values 2023

Exhibit 1: Key Financial Data

| Ticker | Company name | Primary sector | Primary Analyst | Market Cap (mn) | Share price | Price target | Upside to price target (%) | Bull case value, per share | Bear case value, per share | Earnings Per Share | P/E, diluted | | Div. yield (%) | | FCF yield (%) | | Raw Beta | Adjusted Beta | |
|--------|-------------------------------|------------------------------------|---------------------|-----------------|-------------|--------------|----------------------------|----------------------------|----------------------------|--------------------|--------------|-------|----------------|--------|---------------|-------|----------|---------------|------|
| | | | | | | | | | | | 2022e | 2023e | 2022e | 2023e | 2022e | 2023e | | | |
| AMZN.O | Amazon.com Inc | Technology | Nowak, Brian | 1,361,261 | 133.62 | 175.00 | 31.0% | 245.00 | 80.00 | 0.32 e | 2.49 e | NM | NM | 0.0% e | 0.0% e | -1.2% | -0.5% | 0.80 e | 0.87 |
| CBOE.Z | CBOE Global Markets Inc. | Financials | Cyprys, Michael | 12,935 | 121.96 | 140.00 | 14.8% | 196.00 | 81.00 | 6.58 e | 6.99 e | 18.5 | 17.4 | 1.6% e | 1.7% e | NM | NM | 0.68 e | 0.78 |
| CDW.O | CDW Corporation | Technology | Woodring, Erik | 25,002 | 184.87 | 227.00 | 22.8% | 337.00 | 146.00 | 9.62 e | 10.41 e | 19.2 | 17.8 | 1.1% e | 1.2% e | 4.1% | 4.0% | 1.36 e | 1.24 |
| LLY.N | Eli Lilly & Co. | Healthcare | Flynn, Terence | 299,400 | 315.10 | 395.00 | 25.4% | 509.00 | 187.00 | 8.04 e | 9.80 e | 39.2 | 32.2 | 1.2% e | 1.4% e | 2.2% | 2.4% | 0.63 e | 0.75 |
| EDR.N | Endeavor Group Holdings, Inc | Media | Swinburne, Benjamin | 10,704 | 22.79 | 30.00 | 31.6% | 45.00 | 16.00 | 2.71 e | 1.20 e | 8.4 | 19.0 | 0.0% e | 0.0% e | 4.3% | 6.0% | NM | NM |
| XOM.N | Exxon Mobil Corporation | Energy/Utilities | McDermott, Devin | 408,428 | 98.00 | 106.00 | 8.2% | 140.00 | 74.00 | 12.06 e | 10.84 e | 8.1 | 9.0 | 3.6% e | 3.7% e | 14.8% | 11.7% | 0.94 e | 0.96 |
| RACE.N | Ferrari NV | Consumer Discretionary/Industrials | Jones, Adam | 39,275 | 201.90 | 300.00 | 48.6% | 420.00 | 180.00 | 4.93 e | 5.57 e | 40.8 | 36.1 | 0.6% e | 0.8% e | 2.1% | 1.9% | 0.84 e | 0.89 |
| LMT.N | Lockheed Martin Corp | Consumer Discretionary/Industrials | Liwag, Kristine | 114,843 | 433.12 | 522.00 | 20.5% | 690.00 | 328.00 | 21.65 e | 26.30 e | 20.0 | 15.3 | 2.7% e | 2.9% e | 5.7% | 5.7% | 0.81 e | 0.88 |
| MNST.O | Monster Beverage Corp | Consumer Staples | Mohsenian, Dara | 47,504 | 90.16 | 109.00 | 20.9% | 138.00 | 83.00 | 2.35 e | 3.08 e | 38.4 | 29.3 | 0.0% e | 0.0% e | 1.6% | 3.1% | 0.87 e | 0.92 |
| PANW.O | Palo Alto Networks Inc | Technology | Fodderwala, Hamza | 56,743 | 569.51 | 823.00 | 44.5% | 905.00 | 421.00 | 7.56 e | 9.33 e | NM | NA | NA | NA | 3.0% | 3.6% | 1.01 e | 1.00 |
| SPG.N | Simon Property Group Inc | Property | Hill, Richard | 34,975 | 106.84 | 133.00 | 24.5% | 175.00 | 60.00 | 11.82 e | 12.28 e | 9.0 | 8.7 | 6.3% e | 6.6% | 7.6% | 1.99 e | 1.66 | |
| STT.N | State Street Corporation | Financials | Graseck, Betsy | 26,016 | 70.77 | 86.00 | 21.5% | 106.00 | 54.00 | 7.25 e | 8.77 e | 9.8 | 8.1 | 3.4% e | 3.6% e | NM | NM | 1.24 e | 1.16 |
| TMO.N | Thermo Fisher Scientific Inc. | Healthcare | Savant, Tejas | 224,483 | 572.97 | 678.00 | 18.3% | 757.00 | 534.00 | 22.96 e | 24.28 e | 25.0 | 23.6 | 0.2% e | 0.2% e | 3.4% | 4.2% | 0.74 e | 0.83 |
| V.N | Visa Inc. | Technology | Fauvette, James | 427,834 | 206.80 | 291.00 | 40.7% | 336.00 | 189.00 | 7.42 e | 8.47 e | 27.9 | 24.4 | 0.7% e | 0.8% e | 3.8% | 3.7% | 1.00 e | 1.00 |
| ZTS.N | Zoetis Inc. | Healthcare | Wright, Erin | 76,035 | 162.42 | 264.00 | 62.5% | 310.00 | 168.00 | 5.02 e | 5.78 e | 32.4 | 28.1 | 0.7% e | 0.7% e | 2.6% | 3.6% | 0.91 e | 0.94 |

Source: ModelWare and Thomson Reuters, data as of 8/23/2022

Adjusted beta is the 3 year weekly historical beta which is smoothed by multiplying the raw beta by 0.67 plus 0.33

Metrics are calculated using the "for consensus" methodology.

NA = Not Applicable; NM = Not Meaningful

*For RACE.N: Numbers represent EUR, except Market cap, Share price, Price target, Bull case value and Bear case value.

*For SPG.N: Numbers in EPS column represent FFO per share.

*For SPG.N: Numbers in P/E column represent P/FFO per share

Vintage Values 2023

This is the 13th annual edition of *Vintage Values*. In compiling the list, our stock-selection framework blended our analysts' fundamental views with quantitative analysis.

We began by asking each of our North America analysts for their top recommendation for a one-year buy-and-hold investment horizon; more than 50 names were suggested by our analysts. Morgan Stanley Research's Stock Selection Committee (SSC), in conjunction with our US Equity Strategy team, assessed each company's macro exposure, industry positioning, valuation, and risk-reward profile, paying particular attention to the skew of the analysts' Bull- and Bear-Case valuation estimates.

The SSC also considered each stock's ranking within our Quant Strategy team's Quality scoring model. Additionally, the SSC collaborated with our Global Sustainability Research team to integrate ESG analysis into the process.

To arrive at our final list of 15 names, the SSC also considered the sector weighting recommendations of our Chief US Equity Strategist Michael Wilson; *Vintage Values 2023* is broadly aligned with Mike's sector preferences — for instance, it is overweight Health Care and Real Estate.

The list has a bias toward high-quality stocks; although it screens as more expensive than the market on several multiples-based metrics, it is more attractive on key cash-flow-based valuation measures. Additionally, it has a beta below 1. The average stock in the portfolio is currently trading at an 11% premium to the market on forward P/E (20.4 vs. 18.4x for the S&P 500) and a 17% premium on Price/Sales (2.8x vs 2.4x). However, *Vintage Values 2023* is materially less expensive than the index based on Enterprise Value-to-Operating Cash Flow, and carries a more attractive FCF yield (5.0% vs. 4.7% for the market).

Interestingly, at a time when our US Equity Strategy team is highly focused on relative earnings revisions, which have been negative for the market as a whole, *Vintage Values 2023* has a far superior revisions profile vs. the S&P 500: 3-Month Smoothed Revisions are slightly positive, versus negative-3.8% for the index. Further, the portfolio's Up-to-Down revisions ratio, while negative, is more than 40 percentage points above the S&P 500's.

In terms of style, it is weighted toward Growth: 60% of our list is classified as "Growth" by our Quant Research Team's proprietary style model, well above the 39% for the index overall; 7% is classified as "Value" by our Quant model, vs. 25% for the S&P 500 (the remaining 33% are classified as neither Growth nor Value, according to our Quant team's style model). It is slightly more defensive than the market: 33% of the stocks are classified as "Cyclical" vs 41% for the S&P 500, and 27% are "Defensive", vs. 24% for the index.

Our list also favors large-cap stocks; 63% of the names are classified as either mega-cap or large-cap, and the average market cap of \$211 billion is well above the \$74 billion average for the S&P 500. The portfolio's beta is 0.95.

Exhibit 2: Vintage Values 2023 vs S&P 500 as of August 23, 2022

| | Factor | Portfolio | Benchmark | Portfolio vs Benchmark |
|-------------------------------|-------------------------------------|-----------|-----------|------------------------|
| Valuation | Price-to-Book | 5.2x | 4.1x | 1.3x |
| | Price-to-Fwd. Earnings | 20.4x | 18.4x | 1.1x |
| | Price-to-Sales | 2.8x | 2.4x | 1.2x |
| | Price-to-Oper. Cash flow | 15.7x | 14.5x | 1.1x |
| | EV-to-EBIT | 23.7x | 26.7x | 0.9x |
| | EV-Free Cash Flow | 49.5x | 125.2x | 0.4x |
| | Dividend Yield | 1.2% | 2.0% | -0.8% |
| | Total Yield | 2.1% | 3.3% | -1.2% |
| Capital Use and Profitability | Free Cash Flow Yield | 5.0% | 4.7% | 0.3% |
| | Cash-to-Market Capitalization | 31.2% | 16.3% | 1.9x |
| | Capex-to-Sales | 4.4% | 6.8% | 0.7x |
| | Accruals | 11.6% | 7.8% | 1.5x |
| | Incremental Margin | 23.5% | 27.5% | -4.1% |
| | Asset Turnover | 67.1% | 73.0% | 0.9x |
| Growth and Investor Sentiment | Gross Margin | 44.1% | 45.4% | -1.3% |
| | Change in Shares Outstanding | 0.3% | -0.3% | 0.5% |
| | 9-Month Price Momentum | -3.3% | -5.4% | 2.1% |
| | 3-Month Smoothed Earnings Revisions | 0.4% | -3.8% | 4.2% |
| | Up-to-Down Revisions | (43.3%) | (86.3%) | 42.9% |
| Size | Sales Stability | 11.2% | 13.0% | (1.8%) |
| | Beta | 0.95 | 1.00 | 0.9x |
| Size | Market Cap | 210,591 | 73,717 | 2.9x |

Source: Source: Clarifi, FactSet, Refinitiv, as interpreted by Morgan Stanley's Quantitative Equity Research team.
 * The Vintage Values portfolio is equally weighted. .

Exhibit 3: Vintage Values 2023 vs S&P 500 Exposures as of August 23, 2022

| Exposure | Group | Portfolio | Benchmark | Portfolio vs Benchmark |
|---------------------|------------------------|-----------|-----------|------------------------|
| Size | Mega-Cap Stocks | 33.3% | 10.0% | 23.3% |
| | Large-Cap Stocks | 40.0% | 45.2% | -5.2% |
| | Mid-Cap Stocks | 26.7% | 44.4% | -17.7% |
| | Small-Cap Stocks | 0.0% | 0.4% | -0.4% |
| Quality | High | 60.0% | 46.0% | 14.0% |
| | Medium | 0.0% | 3.6% | -3.6% |
| | Low | 6.7% | 4.4% | 2.3% |
| | Junk | 33.3% | 46.0% | -12.7% |
| Style | Growth | 60.0% | 39.2% | 20.8% |
| | Value | 6.7% | 25.2% | -18.5% |
| Cyclical/ Defensive | Cyclical | 33.3% | 41.4% | -8.1% |
| | Defensive | 26.7% | 23.6% | 3.1% |
| Sectors | Energy | 6.7% | 4.6% | 2.1% |
| | Materials | 0.0% | 2.5% | -2.5% |
| | Industrials | 6.7% | 7.9% | -1.3% |
| | Consumer Discretionary | 13.3% | 11.5% | 1.8% |
| | Consumer Staples | 6.7% | 6.7% | 0.0% |
| | Health Care | 20.0% | 14.0% | 6.0% |
| | Financials | 13.3% | 10.7% | 2.6% |
| | Information Technology | 20.0% | 27.8% | -7.8% |
| | Communication Services | 6.7% | 8.3% | -1.7% |
| | Utilities | 0.0% | 3.1% | -3.1% |
| | Real Estate | 6.7% | 2.8% | 3.8% |

Source: Source: Clarifi, FactSet, Refinitiv, as interpreted by Morgan Stanley's Quantitative Equity Research team. * The Vintage Values portfolio is equally weighted. The benchmark portfolio assumes an equally-weighted portfolio for the size, quality, style and cyclical-defensive categories. Sectors use the actual S&P 500 sector weights

'Vintage Values 2022' outperformed the S&P 500. Last year's *Vintage Values* names produced a total return of -4.64% over the period from August 20, 2021 to August 23, 2022, outperforming the S&P 500 by 100basis points over that period.

Exhibit 4: Performance of 'Vintage Values 2022' (August 20, 2021-August 23, 2022)

| Ticker | Company name | Total Return | Contrib. to Portfolio Return |
|--------------------|-------------------------------------|---------------|------------------------------|
| GOOGL.O | Alphabet Inc. | -17.15% | -1.14% |
| APO.N | Apollo Global Management Inc | 6.03% | 0.40% |
| KO.N | Coca-Cola Co. | 16.97% | 1.13% |
| CTSH.O | Cognizant Technology Solutions Corp | -12.73% | -0.85% |
| RACE.N | Ferrari NV | -5.09% | -0.34% |
| GILD.O | Gilead Sciences Inc. | -8.04% | -0.54% |
| JCI.N | Johnson Controls International Plc | -23.19% | -1.55% |
| MSFT.O | Microsoft | -8.40% | -0.56% |
| MDLZ.O | Mondelez International Inc | 2.64% | 0.18% |
| NCR.N | NCR Corp. | -22.55% | -1.50% |
| NOC.N | Northrop Grumman Corp. | 35.20% | 2.35% |
| SYF.N | Synchrony Financial | -29.33% | -1.96% |
| UNH.N | UnitedHealth Group Inc | 26.37% | 1.76% |
| V.N | Visa Inc. | -9.98% | -0.67% |
| WMG.O | Warner Music Group Corp. | -20.33% | -1.36% |
| Total | | -4.64% | -4.64% |
| S&P 500 | | -5.64% | -5.64% |

Source: Source: Thomson Reuters, Bloomberg, Morgan Stanley Research. Data as of August 23, 2022. This assumes the focus list was constituted with equal-weighted positions on August 20, 2021. Results shown represent total absolute return (including dividends) and exclude brokerage commissions and transaction costs.

Risk Reward – Amazon.com Inc (AMZN.O)

Top Pick

AMZN Risk Reward

PRICE TARGET \$175.00

We apply a sum-of-the-parts valuation on AMZN's five businesses (1P, 3P, AWS, Subscription, and Advertising/Other). We value core retail at ~\$500bn based on 1P reaching 1.00% '24 op margins and 3P reaching a 18% EBITDA margin. AWS is worth ~\$790bn, Prime sub revenues are worth ~\$300bn and AMZN's ad business is ~\$190bn.



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$245.00 | BASE CASE | \$175.00 | BEAR CASE | \$80.00 |
|---|----------|---|----------|---|---------|
| ~11x Bull Case '22e EV/EBITDA Disc. Back to '23 | | ~18x EV/ '23 EBITDA | | ~9x Bear Case 23e EV/EBITDA | |
| We apply a sum-of-the-parts valuation on AMZN's five businesses (1P, 3P, AWS, Subscription, and Advertising/Other). We value core retail at ~\$760bn based on 1P reaching 3.5% '24 op margins and 3P reaching a 20% EBITDA margin. AWS is worth ~\$1trln, Prime sub revenues are worth ~\$395bn and AMZN's ad business is ~\$325bn. | | We apply a sum-of-the-parts valuation on AMZN's five businesses (1P, 3P, AWS, Subscription, and Advertising/Other). We value core retail at ~\$500bn based on 1P reaching 1.00% '24 operating margins and 3P reaching a 18% EBITDA margin. AWS is worth ~\$790bn, Prime sub revenues are worth ~\$300bn and AMZN's ad business is ~\$190bn. | | Investments step up. Heavy investments in last mile, fulfillment, digital content, Prime, devices and international expansion markets, and AWS price cuts continue, which along with higher technology & content expense, pressure margins. Our bear case is based on a DCF in which we treat AMZN's operating leases as a full cash expense. | |

OVERWEIGHT THESIS

- Amazon's high-margin businesses continue to allow Amazon to drive greater profitability while still continuing to invest (last mile delivery, fulfillment, Prime Now, Fresh, Prime digital content, Alexa/Echo, India, AWS, etc).
- Amazon Prime membership growth drives recurring revenue and positive mix shift.
- Cloud adoption hitting an inflection point.
- Advertising serves as a key area for both further growth potential and profitability flow-through.

Consensus Rating Distribution



Risk Reward Themes

| | |
|-----------------------|----------|
| Secular Growth: | Positive |
| New Data Era: | Positive |
| Technology Diffusion: | Positive |

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Amazon.com Inc (AMZN.O)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|----------------------------|---------|---------|---------|---------|
| Revenue (\$, mm) | 469,822 | 529,372 | 611,422 | 699,113 |
| Gross Profit (\$, mm) | 198,018 | 229,741 | 283,562 | 334,767 |
| GAAP EBIT (\$, mm) | 24,879 | 18,637 | 32,418 | 40,596 |
| Paid Unit Growth (y/y) (%) | 15.5 | 6.4 | 15.4 | 12.9 |
| AWS Revenue Growth (%) | 37.1 | 32.6 | 27.6 | 23.5 |

INVESTMENT DRIVERS

- Amazon's high-margin businesses continue to allow Amazon to drive greater profitability while still continuing to invest
- Cloud is in a multi-decade secular adoption cycle
- Amazon is gaining share in eCommerce/retail and share of consumers' wallets

GLOBAL REVENUE EXPOSURE



- 0-10% APAC, ex Japan, Mainland China and India
- 0-10% India
- 0-10% Japan
- 0-10% Latin America
- 0-10% Mainland China
- 0-10% UK
- 10-20% Europe ex UK
- 60-70% North America

Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 4/5 BEST | 24 Month Horizon | 5/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Faster than expected AWS rev growth and margin expansion
- 1-day shipping cost transition goes faster than expected
- Amazon succeeds in expanding its TAM (logistics, advertising, grocery, etc)

RISKS TO DOWNSIDE

- Investments step up and continue for longer than expected
- Unit growth slows
- AWS revenue decelerates and /or margins decline

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 60.5% | |
| HF Sector Long/Short Ratio | 1.4x | |
| HF Sector Net Exposure | 8.5% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure – Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e

| | | | | |
|-----------------------------|---------|--|---------|---------|
| Sales / Revenue (\$, mm) | 494,918 | | 529,372 | 533,362 |
| EBITDA (\$, mm) | 67,218 | | 75,761 | 72,627 |
| Net income (\$, mm) | (4,575) | | 3,288 | 3,852 |
| EPS (\$) | (0.45) | | 0.32 | 0.05 |

◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – CBOE Global Markets Inc. (CBOE.Z)

Volatility Boosts Volumes Outlook, Index Options Key Cash Cows

PRICE TARGET \$140.00

Based on 20x base case 2023e operating EPS (implied 14x 2023e EV / EBITDA), which reflects a ~20% premium to S&P (in-line vs historical premium). Target 20x P/E multiple is also in-line with CBOE's historical 3-yr average.

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research

OVERWEIGHT THESIS

- Rising recession risks and elevated market volatility support robust outlook for trading volumes, and transactional revs represent 70% of firm revs.
- CBOE's proprietary index option products are cash cows with pricing power and high incremental margins that are poised to benefit from increased volatility as market participants look to manage and express risks exposure.
- In addition to the cyclical uplift, CBOE has invested in a number of initiatives to support the long-term growth potential of the index suite (i.e. SPX tues/thurs expiries, global trading hours, nanos contracts). While still early days, we can see long term growth to volumes as initiatives scale and gain traction.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

| | |
|---------------|-----------------|
| Disruption: | <i>Positive</i> |
| Market Share: | <i>Positive</i> |
| Self-help: | <i>Positive</i> |

View descriptions of Risk Rewards Themes [here](#)

BULL CASE \$196.00

24x 2023e bull case operating EPS of \$8.19

More positive growth outlook driven by macro tailwinds, strong strategic pivot to data & analytics, successful retail distribution, and resilience in proprietary products. 2023e adj. EBITDA margin of 65.5%.

BASE CASE \$140.00

20x 2023e base case operating EPS of \$6.99

Proprietary index options benefit from volatile macro backdrop. Index options contribute higher fees and margins, boosting earnings outlook. 2023e adj. EBITDA margin of 63%.

BEAR CASE

\$81.00

16x 2023e bear case operating EPS of \$5.04

Macro headwinds, slower than expected strategic pivot, and competitive pressures in proprietary products and cash equities hurt top-line growth and margins. 2023e adj. EBITDA margin of 56%.

Risk Reward – CBOE Global Markets Inc. (CBOE.Z)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|------------------------------|-------|-------|-------|-------|
| Net Revenues (\$, mm) | 1,476 | 1,721 | 1,846 | 1,832 |
| Total Adj. Expenses (\$, mm) | 531 | 664 | 720 | 726 |
| Adj. EBITDA (\$, mm) | 987 | 1,088 | 1,157 | 1,139 |
| Adj. EBITDA Margin (%) | 66.9 | 63.2 | 62.7 | 62.2 |
| Adj. EPS | 6.06 | 6.58 | 6.99 | 6.99 |

INVESTMENT DRIVERS

- Investor appetite for proprietary VIX and SPX products
- Demand for market data (proprietary and non-proprietary) and access/connectivity
- Market share and pricing in US/EU cash equities

GLOBAL REVENUE EXPOSURE



- 0-10% APAC, ex Japan, Mainland China and India
- 10-20% Europe ex UK
- 70-80% North America

Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 4/5 BEST | 24 Month Horizon | 5/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Elevated volumes fueled by prolonged market volatility
- More persistent client engagement and adoption of proprietary products
- Mkt share gains in US/European equities
- Newer initiatives gain traction lifting revs faster

RISKS TO DOWNSIDE

- Reduced investor interest for CBOE's products that weigh on growth
- Greater competitive pressures in cash equities
- Regulatory changes to market structure; headwinds in market data rev



OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 56.9% | |
| HF Sector Long/Short Ratio | 1.5x | |
| HF Sector Net Exposure | 6.9% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e



♦ Mean ♦ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research


Risk Reward – CDW Corporation (CDW.O)

A Long-Term Compounder Set to Benefit from Increasing Services Mix

PRICE TARGET \$227.00

CDW continues to execute and leverage its broad product portfolio & customer end-market exposure. Sirius helps expand FY22 gross margins to 19% and operating margins to 8.2%. Our PT applies a 21.8x P/E (implied by regression of peers) to 2023e EPS of \$10.41.

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART



Source: Refinitiv, Morgan Stanley Research

BULL CASE

28.1x Bull Case FY23e EPS of \$11.98

CDW begins to re-rate on cloud opportunity and grows teens in 2022. Netted down revenue is >30% of gross profit, which drives a re-rating similar to Apple when Services was >30% of GP. Supply improves quicker than expected and demand remains strong, allowing CDW to grow at an over 300 bps growth premium to US IT market growth. Sirius leads to meaningful margin accretion. Shares trade at 28.1x FY23 EPS of \$11.98.

\$337.00

BASE CASE

22x Base Case FY23e EPS of \$10.41

CDW continues to execute and leverage its broad product portfolio & customer end-market exposure. CDW navigates the tight supply environment, and constraints begin to ease in 2H22. CDW benefits from its diversified end-markets, expands netted down revenue mix, and grows revenue inline with its 7.25-8.25% guidance range. Sirius helps expand FY22 GM to 189% and operating margins to 8.2%. Our PT applies 22x P/E (implied by regression of peers) to FY23 EPS of \$10.41.

\$227.00

BEAR CASE


16.5x Bear Case FY23e EPS of \$8.85

Moderating PC demand drives low-to-mid single digit revenue growth in 2022. Geopolitical uncertainty causes downward revisions to US IT market growth of 4% and/or CDW fails to outperform. Pro forma gross margins contract rather than expand due to lower-than-expected netted down revenue. CDW trades at a modest discount to the S&P 500 at 16.5x given concerns around cannibalization of on-prem infrastructure spend from cloud adoption.

OVERWEIGHT THESIS

CDW is a beneficiary of structurally higher IT spending, and with the stock trading at 17x P/E, we believe shares are attractively valued. We believe CDW is set to outperform relative to the rest of our coverage despite the current macro uncertainty as its diversified portfolio allows customers to pivot to growing areas of the IT market. This is evidenced by the fact that CDW has consistently outperformed US IT market growth by ~300 bps on average, even in periods of challenged PC market growth. As a result, we see the potential for upward earnings revisions this year. An increasing mix of Services revenue should also serve as a valuation tailwind, which we reflect in our \$227 price target.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Market Share: *Positive*

Secular Growth: *Positive*

Technology Diffusion: *Positive*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – CDW Corporation (CDW.O)


KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-------------------------------|------|-------|-------|-------|
| Revenue Growth (Y/Y) (%) | 12.7 | 17.1 | 5.4 | 6.9 |
| Gross Margin (%) | 17.1 | 19.0 | 19.2 | 19.3 |
| Non-GAAP Operating Margin (%) | 7.9 | 8.2 | 8.2 | 8.3 |
| Non-GAAP EPS Growth (Y/Y) (%) | 20.8 | 20.7 | 8.3 | 9.6 |

INVESTMENT DRIVERS

- US IT budget growth / declines
- Commercial and public sector PC demand
- IT spending as a % of capex
- Share gains / losses

GLOBAL REVENUE EXPOSURE



- 0-10% UK
- 90-100% North America

Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 2/5 BEST | 24 Month Horizon | 1/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- IT market growth accelerates
- Sirius acquisition accretion exceeds expectations
- PC demand more durable
- Unexpected growth opportunities emerge
- Netted down mix shift drives GM expansion

RISKS TO DOWNSIDE

- Supply constraints cap upside
- Demand fades due to geopolitical uncertainty
- Double ordering in 2021 leads to slower growth in 2022
- PC demand moderates faster
- Accelerating cloud adoption cannibalizes on-prem spend

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 66.2% | |
| HF Sector Long/Short Ratio | 2.2x | |
| HF Sector Net Exposure | 32.9% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2023e

| | | | |
|-----------------------------|--------|--|--------|
| Sales / Revenue (\$, mm) | 25,700 | | 27,291 |
| 25,481 | | | 25,906 |
| EBITDA (\$, mm) | 2,264 | | 2,452 |
| 2,156 | | | 2,294 |
| Net income (\$, mm) | 1,394 | | 1,524 |
| 1,394 | | | 1,436 |
| EPS (\$) | 10.41 | | 11.14 |
| 10.35 | | | 10.59 |

♦ Mean ♦ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – Eli Lilly & Co. (LLY.N) Top Pick

Mounjaro and new product cycles will fuel best growth in industry

PRICE TARGET \$395.00


Our 12-month price target of \$395 is based on a 35x P/E multiple applied to our 3Q 2023 to 2Q 2024 EPS estimate of \$11.29. This multiple is above LLY's 10-year average (20x) and the industry (14.5x) but deserved given the company's growth profile and pipeline optionality.

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



BULL CASE \$509.00

44x bull case 3Q23-2Q24 EPS

Strong commercial momentum across LLY's new product cycles. Tirzepatide is approved by the FDA for obesity indication launches in 2024. Commercial uptake in both T2D and obesity indications is very robust, leading to 2030 sales of \$28bn. We project LLY could post 2025/2030 EPS of ~\$16.90/\$28.23. Competitor Alzheimer's data in 2H22 (and LLY's Donanemab data in 2023) provides further upside optionality.

BASE CASE \$395.00


35x base case 3Q23-2Q24 EPS

We expect the FDA to approve Tirzepatide for obesity indication in 2024. We model '23/25/30 Tirzepatide WW sales of \$2.3bn/\$5.6bn/\$18.9bn. For Donanemab we assume a 50% POS and '30 risk adjusted sales of \$3.2bn. We believe setup into competitor Ph3 data reads is favorable as we see minimal value in LLY stock for Dmab. Top-line growth should drive operating margin leverage (40% in 2025) and we project LLY could post EPS of ~\$15.81/\$23.77 in '25/30.

OVERWEIGHT THESIS

LLY has the most robust new product cycle (and hence growth) outlook in Pharma as the company could launch five new drugs over the next two years (across large end markets such as diabesity, Alzheimer's disease, cancer and immunology), two of which we project could achieve 2030 sales in excess of \$5bn on an un-risk adjusted basis. Our work on Mounjaro (Tirzepatide) for diabetes and obesity underpins our thesis. All in we project that these new launches will boost LLY's top line by 40%+ (2025 vs. 2022) with Mounjaro accounting for half of this, expand operating margins to 40% from 30% (2025 vs. 2022), and put LLY on pace to deliver 2025/2030 EPS of ~\$15.81/\$23.77.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Market Share: *Positive*

Secular Growth: *Positive*

Technology Diffusion: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BEAR CASE \$187.00

18x bear case 3Q23-2Q24 EPS

Tirzepatide is approved by the FDA in obesity, but fails to capture significant market share. Tirzepatide is marginally successful in capturing market share for T2D indication, leading to 2025/2030 sales of \$2.6bn/\$4.3bn.

Risk Reward – Eli Lilly & Co. (LLY.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|------------------------------------|------|-------|-------|--------|
| Total revenues growth (%) | 15.4 | 1.8 | 9.0 | 13.5 |
| Trulicity growth (%) | 27.7 | 17.9 | (0.8) | (10.0) |
| Taltz growth (%) | 23.7 | 14.0 | 13.0 | 7.0 |
| Gross profit growth (%) | 12.5 | 3.4 | 11.6 | 15.5 |
| Operating income, EBITA growth (%) | 4.4 | 10.0 | 20.3 | 30.0 |


CATALYST CALENDAR

| Date | Event | Source: Refinitiv, Morgan Stanley |
|---------------------------|---|-----------------------------------|
| H2 2022 | Lecanemab: BiIB/Eisai's Phase 3 Alzheimer's data | |
| H2 2022 | Gantenerumab: Roche's Phase 3 Alzheimer's data | |
| Q3 2022 | Wegovy: Novo's interim analysis of Phase 3 obesity CVOT trial | |
| 01 Jul 2022 - 30 Jun 2023 | Donanemab: FDA action on accelerated approval in Alzheimer's | |

INVESTMENT DRIVERS

- New product cycles
- Operating margin expansion
- Near term data readouts

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 5/5 BEST | 24 Month Horizon | 5/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Tirzepatide has positive outcomes trials in obesity, opens new market
- Donanemab is successful in the ongoing Ph3 program and is approved
- New product cycles drive best in class revenue growth and operating margin expansion

RISKS TO DOWNSIDE

- Tirzepatide isn't approved for obesity
- Donanemab fails in the ongoing Ph3 Alzheimer's disease program
- New product cycles disappoint, LLY invests more to maintain operating margin

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 56% | |
| HF Sector Long/Short Ratio | 2.2x | |
| HF Sector Net Exposure | 20.5% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).


MS ESTIMATES VS. CONSENSUS

FY Dec 2023e



Source: Refinitiv, Morgan Stanley Research

SUSTAINABILITY & ESG




Risk Reward – Endeavor Group Holdings, Inc (EDR.N)

Top Pick

Play on Premium Talent, IP, and Sports Assets

PRICE TARGET \$30.00

Our \$30 PT is based on ~15x fwd. base case EBITDA (MS-defined) and is supported by our DCF-driven fair market value.



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART



Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target


Source: Refinitiv, Morgan Stanley Research

| BULL CASE | \$45.00 | BASE CASE | \$30.00 | BEAR CASE | \$16.00 |
|---|---------|---|---------|---|---------|
| ~19x fwd. EBITDA | | ~15x fwd. EBITDA | | ~10-11x fwd. EBITDA | |
| We assume a more rapid re-opening recovery driving top line revenue CAGR of 8-9%, 100-150bps ahead of our base case. At the UFC, we expect the next round of domestic US rights to renew at a 2.5x AAV. Total company operating margins hit ~23% by 2023. | | We see a revenue CAGR of ~7-8% between '21-'24E, driven by a return to live events and rising monetization opportunities at WME. At the UFC, we expect the next round of US rights to renew at 2.0x AAV. Total company operating margins hit 22% by 2023. | | We assume a more tepid re-opening and our revenue growth CAGR of 6-7% is 50-150bps lower than our base case. At the UFC, we expect the next round of domestic US rights to renew at a 1.5x AAV. Total company operating margins hit ~22% by 2023. | |

OVERWEIGHT THESIS

- Endeavor offers exposure to powerful growth drivers in the industry, including appreciating sports rights, streaming content spend, and re-opening
- The UFC is a strategic asset with real scarcity value and upcoming rights renewal in 2026
- Lower growth live events and marketing agencies and company financial leverage provide some risk to shares

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

| | |
|-----------------|----------|
| Secular Growth: | Positive |
| Self-help: | Positive |
| Market Share: | Positive |

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Endeavor Group Holdings, Inc (EDR.N)


KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|----------------------------------|-------|-------|-------|-------|
| OSP Revenues (\$, mm) | 1,108 | 1,333 | 1,403 | 1,492 |
| OSP EBITDA (\$, mm) | 538 | 616 | 614 | 663 |
| Representation Revenues (\$, mm) | 1,960 | 1,596 | 1,706 | 1,809 |
| Representation EBITDA (\$, mm) | 383 | 516 | 559 | 601 |
| UFC EBITDA (\$, mm) | 515 | 579 | 606 | 655 |

INVESTMENT DRIVERS

- Any change, better or worse, in the macro environment and re-opening timelines
- Popularity of UFC and demand for niche sports IP content driving streaming platform scale
- Increasing or moderating pace of industry content spend

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

RISKS TO PT/RATING

RISKS TO UPSIDE

- More rapid re-opening driving faster top-line
- Higher efficiencies in cost base driving operating leverage margins
- UFC domestic rights renewal of 2.5x in 2026e

RISKS TO DOWNSIDE

- Worsening macro conditions and a slower re-opening recovery
- Higher talent costs and more cost savings reversing, driving lower operating margins
- UFC domestic rights renewal of 1.5x in 2026e




OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 95.5% | |
| HF Sector Long/Short Ratio | 2.3x | |
| HF Sector Net Exposure | 11.1% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e



♦ Mean ♦ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – Exxon Mobil Corporation (XOM.N)


Spending cuts and margin recovery has improved FCF & dividend sustainability

PRICE TARGET \$106.00

Base case of \$106/sh which is a 50/50 blend of 1) a target multiple of 6.5x 2023e EV/DACF (\$112/share) and 2) our discounted cash flow value of \$100/share (with a WACC of 8.1% and terminal EV/EBITDA multiple of 5.9x).



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

BULL CASE \$140.00

8.2x 2023e EV/DACF of \$79 B

Bull case of \$140/sh is based on a 50/50 blend of 1) a target multiple of 6.5x 2023e EV/DACF (\$133/share) and 2) our discounted cash flow value of \$147/share. Scenario assumes \$87.50 WTI, \$90 Brent, \$3.75 Henry Hub, and refining margins increase ~10%.

BASE CASE \$106.00

7.3x 2023e EV/DACF of \$67 B

Base case of \$106/sh which is a 50/50 blend of 1) a target multiple of 6.5x 2023e EV/DACF (\$112/share) and 2) our discounted cash flow value of \$100/share (with a WACC of 8.1% and terminal EV/EBITDA multiple of 5.9x). Scenario assumes long-term (2025+) \$67.50 WTI, \$70 Brent, \$3.25 Henry Hub.

BEAR CASE \$74.00

6.7x 2023e EV/DACF of \$53 B


Bear case of \$74/sh is based on a 50/50 blend of 1) a target multiple of 6.5x 2023e EV/DACF (\$81/share) and 2) our discounted cash flow value of \$66/share. Scenario assumes \$47.50 WTI, \$50 Brent, \$2.75 Henry Hub, and refining margins decline ~10%.

OVERWEIGHT THESIS

■ **Improving FCF outlook and dividend sustainability.** With a more constructive commodity price outlook, lower capital spending, and additional cash operating cost savings, the dividend is covered in 2021 and averages >100% over the next 5-years on our estimates. Improving dividend sustainability supports yield compression for XOM relative to CVX.

■ **Cost cuts defend the dividend.** In 2020, XOM reduced 2022-25 spending plans to \$20-25B from \$30-35B (recently extended to 2027), improving dividend sustainability while limiting further pull on the balance sheet. Additionally, XOM is targeting \$6B in structural operating cost reductions by 2023 which should put upward pressure on consensus FCF estimates

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Renewable Energy: *Positive*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Exxon Mobil Corporation (XOM.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|----------------------------|-------|-------|-------|-------|
| Oil Production (Mbbl/d) | 2,017 | 2,084 | 2,178 | 2,284 |
| Total Production (Mboe/d) | 3,712 | 3,693 | 3,725 | 3,826 |
| Realized Oil Price (\$) | 59.90 | 92.25 | 83.31 | 74.32 |
| Realized Gas Price (\$) | 7.11 | 9.33 | 6.90 | 5.92 |
| EBITDA Margin per Boe (\$) | 39.54 | 74.28 | 62.02 | 48.46 |


CATALYST CALENDAR

Source: Refinitiv, Morgan Stanley

INVESTMENT DRIVERS

- Capex
- Capital efficiency
- Commodity prices including oil & gas, LNG, crack spreads, and chemicals margins
- Major capital projects including Guyana, Permian, Brazil, Papua New Guinea LNG, Mozambique

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 5/5 BEST | 24 Month Horizon | 1/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Higher commodity prices, including liquefied natural gas (LNG)
- Successful execution of major capital projects
- Permian well performance improvements
- Additional cost cuts

RISKS TO DOWNSIDE

- Lower commodity prices
- Cost overruns on major capital projects
- Service cost inflation in the Permian erodes returns
- Geopolitical risk could impact production volumes and/or returns; Guyana is a particular focus now.


OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 46.4% | |
| HF Sector Long/Short Ratio | 2x | |
| HF Sector Net Exposure | 6.7% | |

Refinitiv, MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS


FY Dec 2023e



◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

SUSTAINABILITY & ESG



Risk Reward – Ferrari NV (RACE.N) Top Pick


Leading Luxury Brand & High Quality Earnings - On a Road to EVs

PRICE TARGET \$300.00

Our \$300 PT has been derived using a 18 year DCF Valuation to 2040 applying a WACC of 8.4%. We apply an exit multiple of 17x. Exit assumptions also include a 27.4% EBIT margin & 38.7% EBITDA margin.



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

BULL CASE \$420.00

~30.8x 2024e Bull Case EBITDA of ~€2.4bn

Firing on all 12 cylinders. RACE beats guidance, releases long-term plans and the market prices in higher growth and profitability on outer reference years, while retaining a multiple greater than luxury brand peer leader, Hermes, as well as the market assuming better-than-expected cost performance on incremental volume, mix and ancillary revenue opportunities. The shift to EVs is extremely profitable and customers embrace Ferrari BEVs.

BASE CASE

~26.4x 2024e EBITDA of ~€2.0bn

Compounding growth potential and strong execution. Global shipments of 13.0k units in 2022, growing at a 7.3% CAGR to 2030 ending at ~21k shipments. Adj. EBITDA margins remain 35% in 2022 on strong mix & pricing. RACE trades at a justified premium to luxury brands, but at a discount to luxury leader, Hermes. Opportunity to grow organically via: new customers, new segments & geographically. RACE continues to maintain a 12+ month customer orderbook. EVs are additive to brand & margins.


\$300.00

MS Rating

OVERWEIGHT THESIS

Growth potential and strong execution. Global shipments of >13k units in 2022, growing at a 7.3% CAGR to 2030 ending at ~21.0k shipments. Adj. EBITDA margins remain 35% in 2022 on strong mix and pricing. Ferrari trades at a justified premium to luxury brands, but at a discount to luxury leader, Hermes, albeit with more opportunity to grow organically via: new customers, new segments and geographically in China & Asia-Pac, as well as exhibiting a unique moat with a world renowned brand and a 12+ month customer orderbook.

Consensus Rating Distribution



Risk Reward Themes

Pricing Power: Positive

View descriptions of Risk Rewards Themes [here](#)

BEAR CASE

\$180.00

~17.6x 2024e Bear Case EBITDA of ~€1.8bn

Burnout and re-rate down. Global shipments do not rise as expected on a weaker macro backdrop, with more persistent demand problems & cancellations ensuing. Production halts and recalls. Margins come in over 200 bps below base case as costs are higher than anticipated & new models contribute less to mix. RACE trades closer to lower end of luxury peer group. RACE LT targets lower than anticipated. BEVs fail to deliver on both customer demand & margins. Loss of brand relevance.

Risk Reward – Ferrari NV (RACE.N)


KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|------------------------------|----------|----------|----------|----------|
| ASPs (€) (€) | 320,355 | 317,782 | 327,315 | 337,135 |
| Units | 11,155.0 | 13,001.2 | 13,838.8 | 14,810.7 |
| EBITDA (€mm) (€, mm) | 1,531 | 1,721 | 1,800 | 2,001 |
| Diluted EPS (€) (€) | 4.50 | 4.93 | 5.57 | 6.28 |
| Free Cash Flow (€mm) (€, mm) | 550 | 784 | 710 | 804 |

INVESTMENT DRIVERS

- New Product Launches
- ASPs, Sales, Margins, FCF
- Residual Values
- Guidance Revisions
- F1 Performance
- Brand Value

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

SUSTAINABILITY & ESG



RISKS TO PT/RATING

RISKS TO UPSIDE

- Robust orderbook, new customers, new models, shipment growth
- High ASPs, strong mix & margins
- Commoditization of EVs mean more value is placed on Ferrari ICE

RISKS TO DOWNSIDE

- Weakness in demand or production issues
- Execution risk around brand expansion
- Increases in engineering costs to EV migration & EVs could hurt value proposition
- F1 R&D costs higher than expected
- Austerity limits perception of Ferrari owners

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 86.6% | |
| HF Sector Long/Short Ratio | 1.4x | |
| HF Sector Net Exposure | 8.5% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e

| EPS | 4.35 | | 4.93 | 5.28 |
|-----|------|--|------|------|
| (€) | 4.88 | | | |

| EBITDA | 1,330 | | 1,721 | 1,809 |
|---------|-------|--|-------|-------|
| (€, mm) | 1,694 | | | |

| EBIT | 1,163 | | 1,178 | 1,252 |
|---------|-------|--|-------|-------|
| (€, mm) | 1,189 | | | |

| Sales / Revenue | 4,868 | | 4,868 | 5,015 |
|-----------------|-------|--|-------|-------|
| (€, mm) | 4,924 | | | |

| Net income | 793 | | 903 | 967 |
|------------|-----|--|-----|-----|
| (€, mm) | 894 | | | |

♦ Mean ◆ Morgan Stanley Estimates


Source: Refinitiv, Morgan Stanley Research

Risk Reward – Lockheed Martin Corp (LMT.N)


A Well-Balanced Bellwether

PRICE TARGET \$522.00

We arrive at our price target of \$522 by placing a ~18.5x multiple on base case 2023E EPS of \$28.30. Lockheed Martin has typically traded in line with peers on most metrics, reflecting its solid performance, quality balance sheet, and high-end portfolio of products.



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$690.00 | BASE CASE | \$522.00 | BEAR CASE | \$328.00 |
|--|----------|--|----------|--|----------|
| ~21x P/E multiple on CY2023E EPS | | ~18.5x P/E multiple on CY2023E EPS | | ~13x P/E multiple on CY2023E EPS | |
| Our bull case is reflective of the following in 2023E: | | Our base case is reflective of the following in 2023E: | | Our bear case is reflective of the following in 2023E: | |
| Multiple: ~21x P/E on bull case EPS | | Multiple: ~18.5x P/E on base case EPS | | Multiple: ~13x P/E on base case EPS | |
| Revenue: ~4% CAGR (2021-2026) | | Revenue: ~3.5% CAGR (2021-2026) | | Revenue: ~2% CAGR (2021-2026) | |
| EBITDA Margin: ~16% | | EBITDA Margin: ~14% | | EBITDA Margin: ~13.5% | |
| Tax Rate: ~18% | | Tax Rate: ~18% | | Tax Rate: ~18% | |

OVERWEIGHT THESIS

We view Lockheed as one of the most well positioned companies with leadership positions in hypersonics, directed energy, autonomy, multi-domain operations and space. Additionally the company has one of the most well insulated and visible earnings profiles in the group as a result of the F-35 program that makes up nearly 30% of total company revenues that is paired with multi-decade visibility. We expect the stock to outperform peers due to its defensible portfolio, steady execution, strong free cash flow generation, and underlevered balance sheet.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Lockheed Martin Corp (LMT.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-----------------------|------|-------|--------|--------|
| Sales (mm) | NA | NA | 67,182 | 69,971 |
| EPS | NA | NA | 28.30 | 29.05 |
| Operating Income (mm) | NA | NA | 8,716 | 8,907 |
| Free Cash Flow (mm) | NA | NA | 6,511 | 6,646 |

INVESTMENT DRIVERS

- F-35 provides visibility into 2040, although production growth will slow in coming years
- Biden's Defense Policy and resulting DoD budget
- Emerging Pension headwinds
- U.S. DoD investments in advanced capabilities

GLOBAL REVENUE EXPOSURE



- 0-10% APAC, ex Japan, Mainland China and India
- 0-10% Europe ex UK
- 0-10% India
- 0-10% Japan
- 0-10% Latin America
- 0-10% MEA
- 0-10% UK
- 70-80% North America


Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|---------------------------|---------------------|---------------------------|--------------------|
| 3/5 BEST | 24 Month Horizon | 3/5 MOST | 3 Month Horizon |
|---------------------------|---------------------|---------------------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

SUSTAINABILITY & ESG



RISKS TO PT/RATING

RISKS TO UPSIDE

- Increase in perceived or realized security threats
- Easing export policy stimulates growth in international sales

RISKS TO DOWNSIDE

- Decrease in perceived or realized security threats
- Tightening of export policy hinders growth in international sales
- New entrants from commercial players



OWNERSHIP POSITIONING

| | | |
|-----------------------------------|-------|--|
| Inst. Owners, % Active | 44.5% | |
| HF Sector Long/Short Ratio | 1.4x | |
| HF Sector Net Exposure | 6.7% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e



♦ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – Monster Beverage Corp (MNST.O)

Top Pick

Valuation Does Not Reflect Outsized LT Growth Prospects

PRICE TARGET \$109.00


Our PT is derived from a ~35x CY23e P/E, with rebounding energy drink trends in the US and International markets post COVID-19 disruptions, particularly in US gas & convenience.

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$138.00 | BASE CASE | \$109.00 | BEAR CASE | \$83.00 |
|---|----------|---|----------|---|---------|
| ~43x CY23e Bull Case EPS | | ~35x CY23e Base Case EPS | | ~28x CY23e Bear Case EPS | |
| Topline growth of high-teens%. Market share gains and building category growth post COVID drives 500/750 bps of US/Int'l revenue upside, lower commodities drive 100 bp of gross margin upside, and a consolidation premium increases, driving multiple expansion to ~43x CY23e P/E, in line with MNST's peak in recent years. | | MNST delivers ~low DD% topline growth (HSD% US and ~high-teens% international). Valuation expands to ~35x CY23e P/E, reflecting accelerating growth. | | Topline weakness. Market share pressure from competitive brands, macro weakness, and decelerating category growth drives 500 bps of US revenue downside and 750 bps internationally. Reinvestment comes in higher than our forecast, compressing the multiple to ~28x CY23e P/E. | |


OVERWEIGHT THESIS

Topline Re-accelerating Post COVID-19

Impacts: We forecast MNST topline re-accelerating to LDD% growth annually the next few years post COVID, above consensus, and driven by high teens international growth.

Compelling Valuation: We believe MNST's valuation looks compelling, with our 12% LT topline growth forecast above the 9% rate the market is pricing in from an implied DCF standpoint and consensus forecasts.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

| | |
|-----------------|----------|
| Market Share: | Positive |
| Pricing Power: | Positive |
| Secular Growth: | Positive |

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Monster Beverage Corp (MNST.O)


KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|---|---------|-------|-------|-------|
| Net Sales % local currency growth (%) | 19.2 | NA | NA | NA |
| US Sales % growth (%) | 13.5 | NA | NA | NA |
| International Sales % local currency growth (%) | 30.7 | NA | NA | NA |
| Gross Margin Bps Change | (313.6) | NA | NA | NA |
| EPS % Growth (%) | (2.1) | NA | NA | NA |

INVESTMENT DRIVERS

- Building international topline momentum
- US scanner data trends
- Less competitive threat from smaller players and Coke Energy
- Inflecting gross margins
- COVID-19 impact

GLOBAL REVENUE EXPOSURE



- 0-10% APAC, ex Japan, Mainland China and India
- 0-10% Japan
- 0-10% Latin America
- 0-10% MEA
- 0-10% UK
- 10-20% Europe ex UK
- 60-70% North America

Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 5/5 BEST | 24 Month Horizon | 4/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

Coke Energy launch in the US is unsuccessful, higher contribution from innovation (including Reign), higher int'l sales growth & market share gains, early resolution of COVID-19.

RISKS TO DOWNSIDE

Weaker macro/higher unemployment impact on category, smaller brands gain more market share in the US, lower gross margins (product/geographic mix), int'l margins weaker than our forecast, and COVID-19 impacts linger.


OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 66.8% | |
| HF Sector Long/Short Ratio | 1x | |
| HF Sector Net Exposure | 0.1% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure – Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e



◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – Palo Alto Networks Inc (PANW.O)

Top Pick

Durable FCF Growth Not Reflected in Current Multiple

PRICE TARGET \$823.00


Based on 29x Base Case 2024e FCF per share of \$29.59, Discounted Back at 10.3% WACC

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART



Source: Refinitiv, Morgan Stanley Research

BULL CASE \$905.00

30x Bull Case 2024e FCF per share of \$31.71

Consolidating the Broader Security

Market. Total revenue grows at a 22% CAGR over the next 2 years and reaches \$9.4B by CY24, still a small % of the >\$80B in spending in security product and services. Operating margins move to ~21% by CY24 due to robust new business growth with FCF as a % of rev. of 37%. PANW trades 30x EV/FCF multiple in CY24, supported by 23% CAGR FCF growth, and discounted back at 10.3% WACC.

BASE CASE \$823.00

29x Base Case 2024e FCF per share of \$29.59

Sustaining Above Market Growth. PANW sustains an 5% CAGR to reach 106K customers in CY24. Cumulative lic/customer grows at a 10% CAGR and total revenue reaches \$8.8B by CY24. Operating margins improve to ~22% by CY24 through G&A and R&D leverage and a growing recurring rev. base. FCF as a % of rev. at ~37% by CY24 and a robust growth rate sustains 29x EV/FCF in CY24, a multiple relatively in line with large cap security software peers, and discounted back at 10.3% WACC.

BEAR CASE \$421.00

17x Bear Case 2024e FCF per share of \$25.15


Slowing Growth. Prolonged macro slowdown and slower firewall demand persists, while new product traction stalls. Total revenue growth slows to 16% from CY22-CY24, as the new customer adds slow and expansion of existing customer becomes more muted. PANW trades at 17x EV/FCF on CY24.

OVERWEIGHT THESIS

■ Palo Alto Networks offers a disruptive platform, well positioned to address the evolving threat landscape. We believe Palo Alto Networks will continue to differentiate itself from its peers as it proves out a broader TAM around a NextGen Security Platform (and executing to that opportunity).

■ With strong secular positioning and the drive towards higher operating margins, we remain confident in the durability of our FCF estimates. Currently trading at 22x CY23e FCF vs. our model, which looks for ~26% FCF CAGR from CY22-24e, we continue to see attractive risk/reward in PANW shares.

Consensus Rating Distribution



MS Rating

Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Secular Growth: Positive

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Palo Alto Networks Inc (PANW.O)


KEY EARNINGS INPUTS

| Drivers | 2022 | 2023e | 2024e | 2025e |
|--|------|-------|-------|-------|
| Product & Licensing Revenue YoY Growth (%) | 21.7 | 5.0 | 2.8 | 4.0 |
| Total Billings YoY Growth (%) | 36.6 | 20.2 | 13.0 | 22.0 |
| Non Firewall Billings YoY Growth (%) | 63.7 | 38.5 | 25.8 | 33.5 |
| Free Cash Flow Margin (%) | 32.6 | 33.9 | 34.6 | 36.9 |

INVESTMENT DRIVERS

- Firewall refresh activity sustains through CY22/23
- New product introductions and greater subscription attach
- Faster adoption of non-firewall offerings (Prisma Cloud/Access, Cortex)

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate

View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 3/5 BEST | 24 Month Horizon | 3/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Stronger refresh cycle and higher firewall attach rates
- Faster uptake of new Cloud-based Next-Gen Security solutions

RISKS TO DOWNSIDE

- Executive turnover could drive greater than expected sales disruption
- Slowing firewall refreshes could drive a greater than expected impact to PANW's top line growth
- An increasingly competitive environment could necessitate additional S&M spending, limiting margin leverage.

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 70% | |
| HF Sector Long/Short Ratio | 2.2x | |
| HF Sector Net Exposure | 32.9% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Jul 2023e

| | | | | |
|-----------------------------|-------|--|-------|-------|
| Sales / Revenue (\$, mm) | 6,663 | | 6,785 | 6,910 |
| | | | 6,856 | |

| | | | | |
|--------------------|-------|--|-------|-------|
| EBITDA (\$, mm) | 1,428 | | 1,477 | 1,495 |
| | | | 1,428 | |

| | | | | |
|------------------------|-------|--|-------|-------|
| Net income (\$, mm) | 1,011 | | 1,043 | 1,090 |
| | | | 1,053 | |

| | | | | |
|-------------|------|--|------|------|
| EPS (\$) | 8.30 | | 9.33 | 9.80 |
| | | | 9.37 | |

◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Risk Reward – Simon Property Group Inc (SPG.N)

Best In Class Mall Operator; Conviction in Recovery Path Grows

PRICE TARGET \$133.00

We apply an ~11x multiple to our '23e FFO of \$12.28 to arrive at our \$133 PT. This multiple compares to the 5yr avg of 12x and the 10yr avg 15x. We model FCF of ~\$3.5bn in 2025e versus \$2.73bn in 2019 as we assume there is a 4.5% permanent impairment in total (consolidated & unconsolidated property) NOI in 2025 vs 2019. DCF with a 8.2% cost of equity (5.2% ERP; 3.5% risk free rate) & 1.5% terminal growth suggests intrinsic value of \$133.



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$175.00 | BASE CASE | \$133.00 | BEAR CASE | \$60.00 |
|---|----------|---|----------|--|---------|
| ~14x 2023e \$12.49 FFO | | ~11x 2023e \$12.28 FFO | | ~5x 2023e \$11.68 FFO | |
| We apply a ~14x multiple that is 6x below the peak multiple of 20x, is below the current strip group avg. multiple on '22, and is 0.7x below the 10 year avg multiple. We model FCF of ~\$3.6bn in 2025e versus \$2.73bn in 2019 as total NOI recovers to 1% above '19 levels in '25. Net debt to EBITDA falls to 4.9x in 2025. Our analysis is supported by a DCF with 2.5% terminal growth and a 7.5% cost of equity (70bps tighter than base case) that suggests intrinsic value of \$181. | | Our ~11x multiple compares to the 5yr average of 12.0x and the 10yr average of 15x. We model FCF of ~\$3.5bn in 2025e versus \$2.73bn in 2019 as we assume there is a 4.5% permanent impairment in total NOI for SPG in 2025 vs 2019. Net debt to EBITDA falls to 5.2x in 2025. Our analysis is supported by a DCF with 1.5% implied terminal growth and a ~8.2% cost of equity (5.2% equity risk premium and 3.5% risk free rate) suggests intrinsic value at \$133. | | We apply a 5x multiple to our 2023e FFO of \$11.68 to arrive at our bear PT of \$60. This multiple compares to the GFC and COVID troughs multiple of 4.6x. We model FCF of ~\$3.0bn in 2025e versus \$2.73bn in 2019 as we assume there is a ~11% permanent impairment in total NOI for SPG in 2025 vs 2019. Net debt to EBITDA is roughly flat at 6x in '23-'25. SPG is the only remaining public mall REIT as peers face even greater challenges leading to bankruptcy risk. | |

OVERWEIGHT THESIS

We expect SPG to prove to be a long term winner from the shake-up in retail given its strong balance sheet and ability to self-fund (re)development costs with FCF generation. Three factors differentiate their portfolio: 1) malls contributed only ~55% of total NOI, 2) after a 35% rationalization in the mall landscape, we estimate a ~4.5% hit to total NOI and 3) greater negotiating leverage with tenants post the acquisition of TCO's higher quality malls. We expect the stock to re-rate to an FFO multiple of ~11x that is ~1x below the 5yr avg and ~3.5x below the 10yr avg.

Consensus Rating Distribution



Risk Reward Themes

Disruption: *Negative*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Simon Property Group Inc (SPG.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-------------------------------------|------|-------|-------|-------|
| FFO Growth (Row 99) (%) | 31.0 | (1.0) | 3.9 | 3.9 |
| Dividend Payout Ratio (Row 108) (%) | 53.0 | 59.7 | 59.5 | 57.1 |
| Same Store NOI Growth (Row 122) (%) | 16.4 | 2.8 | (0.4) | 1.8 |

INVESTMENT DRIVERS

- Integrating TRG following acquisition
- Earnings from retail investments
- +\$1 billion per year development / redevelopment project pipeline
- SPG's strategy focuses on owning shopping centers across the price spectrum; class A malls to premium outlets

GLOBAL REVENUE EXPOSURE



- 0-10% APAC, ex Japan, Mainland China and India
- 0-10% Europe ex UK
- 0-10% Japan
- 90-100% North America

Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| 3/5 BEST | 24 Month Horizon | 3/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|
| | | | |

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Retail tenants store closures and bankruptcies moderate
- A weaker dollar could be a tailwind for spending in tourist centric locations
- Major acquisition or stock buybacks

RISKS TO DOWNSIDE

- Fixed lease income declines in absolute terms
- COVID-19 impact and recession permanently impair top line revenues
- Debt covenant breaches
- Tenant bankruptcies


OWNERSHIP POSITIONING

| | | |
|----------------------------|------|--|
| Inst. Owners, % Active | 51% | |
| HF Sector Long/Short Ratio | 1.1x | |
| HF Sector Net Exposure | 0.4% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure – Short Exposure).

MS ESTIMATES VS. CONSENSUS


FY Dec 2022e



◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

SUSTAINABILITY & ESG



Risk Reward – State Street Corporation (STT.N)

Driving Efficiencies

PRICE TARGET \$86.00

Our price targets are set by triangulating PE, PB vs ROE (a deconstructed PE) and cost of equity relative to our outlook for asset growth, credit risk, operating efficiency and capital return. Target Price reflects a 10x 2023 PE.



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

BULL CASE \$106.00

12x Bull Case 2023 EPS

Resilient economic growth. Deglobalization drives accelerating on-shoring, resulting in strong real wage growth. Gen Y enters heavy consumption years, increasing loan growth. Gen Z enters workforce, increasing productivity. Credit remains benign. Commercial loan growth accelerates on inventory / infrastructure/ capex buildout. Capital markets revenues bounce back strongly in 2023. Unemployment flat. Fed rate hikes bring inflation down to ~2% by YE 2023 without causing a recession.

BASE CASE \$86.00

10x Base Case 2023 EPS

Slowing economic growth. Inflation is a capital call as borrowers need more funding. QT slows deposit growth and increases deposit and other funding costs. Result is higher lending standards, slowing loan growth. Higher rates crimp levered borrowers. Credit losses rise to 2019 levels for C&I. SP500 at 3900 in June 2023. Recession fear drives 2/10 curve inversion. Buybacks suspended through 3Q22.

\$86.00

BEAR CASE

\$54.00

9x Bear Case 2023 EPS

Recession. Stubbornly high inflation drives Fed to raise rates faster/higher than forward curve, causing sharper demand destruction. Unemployment spikes. C&I losses rise to recessionary levels. Capital markets related revenues under pressure for longer. Buybacks are halted across the board.

OVERWEIGHT THESIS

- Overweight on valuation, as we think STT should trade at 10x 2023 PE or 1.7x PB given our expectation for a 1.3% ROE in 2023. Current valuation implies a 13% cost of equity on a relatively low risk stock, too high in our opinion.
- STT is one of the most rate-sensitive names in our coverage. That's particularly true on the short end, as a 50bp increase in front end rates increases EPS by 9%.
- STT is laser focused on driving efficiencies and delivering positive operating leverage, even in an inflationary environment. We model over 200bps of positive operating leverage in 2023

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

- Contrarian: *Positive*
Self-help: *Positive*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – State Street Corporation (STT.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-----------------------------|------|--------|-------|-------|
| NIM (%) | 0.74 | 0.98 | 1.26 | 1.42 |
| Fee Growth, Y/Y (%) | 5.4 | (3.3) | 12.3 | 2.3 |
| EOP AUCA Growth, Y/Y (%) | 12.6 | (13.3) | 15.7 | 4.0 |
| EOP AUM Growth, Y/Y (%) | 19.4 | (16.9) | 2.0 | 3.0 |
| Operating Leverage, Y/Y (%) | 0.1 | 1.2 | 1.7 | 2.6 |


CATALYST CALENDAR

| Date | Event | Source: Refinitiv, Morgan Stanley |
|---------------------------|--|-----------------------------------|
| 12 Sep 2022 | State Street Corp at Barclays Global Financial Services Conference | |
| 17 Oct 2022 - 21 Oct 2022 | Q3 2022 State Street Corp Earnings Release | |
| 17 Jan 2023 - 23 Jan 2023 | Q4 2022 State Street Corp Earnings Release | |
| TBD | BBH Acquisition Approval | |

INVESTMENT DRIVERS

- BBH Deal Closure
- Positive Operating Leverage
- Global equity markets
- Global bond markets
- Expense management
- Higher rates
- Non-interest bearing deposit flows
- Fee rate compression

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

RISKS TO PT/RATING

RISKS TO UPSIDE

- BBH Acquisition is Approved and Closes
- Higher rates sooner
- Increased expense cuts that don't impact customer service quality
- Higher FX Volatility
- Weaker USD

RISKS TO DOWNSIDE

- Weaker than expected financial markets
- Pressure on long end of the curve and/or delayed rate hikes
- Margin pressure on servicing fee rates
- Stronger USD
- Geopolitical risks


OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 62.6% | |
| HF Sector Long/Short Ratio | 1.5x | |
| HF Sector Net Exposure | 6.9% | |

Refinitiv, MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e




♦ Mean ♦ Morgan Stanley Estimates
Source: Refinitiv, Morgan Stanley Research

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 2/5 BEST | 24 Month Horizon | 5/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

SUSTAINABILITY & ESG




Risk Reward – Thermo Fisher Scientific Inc. (TMO.N)

Top Pick

Leading Consolidator with a Durable and Significant COVID-19 Tailwind


PRICE TARGET \$678.00

Our PT is based on a target forward multiple of ~23.5x EV/2022 EBITDA, premium to peers trading at ~22x.



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$757.00 | BASE CASE | \$678.00 | BEAR CASE | \$534.00 |
|--|----------|--|----------|---|----------|
| Higher COVID tailwind, robust base business demand | | Continued organic growth and smart M&A | | Prolonged COVID-19 impact stunts growth | |
| Our Bull Case valuation assumes greater COVID-19 tailwinds in 2022 than our base case, coupled with a faster recovery in the base business. In particular, we expect ramping CDMO services revenue from manufacturing a number of COVID-19 vaccines in addition to potential resurgence of COVID-19 spread globally driving robust demand for COVID-19 related testing kits and reagents through 2022. We use a target 2022 EV/EBITDA multiple of 21.5x. | | Our Base Case valuation assumes recovery of the base business, coupled with PPD integration and COVID-19 vaccine manufacturing representing a meaningful tailwind for 2022 growth. We use a target 2022 EV/EBITDA multiple of 23.5x. | | Our Bear Case valuation assumes greater COVID-19 headwinds in the base business coupled with a more modest COVID-19 tailwind and a difficult comp, resulting in lower revenue growth in 2022. We use a target 2022 EV/EBITDA multiple of 21x. | |

OVERWEIGHT THESIS

Driven by end market strength and share gains in Biopharma and emerging markets, we expect TMO to meaningfully outpace peers, with diversification and scale embedding best-in-class resilience and flexibility. M&A optionality and durable COVID-19 upside further support our Overweight thesis.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Market Share: *Positive*View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Thermo Fisher Scientific Inc. (TMO.N)


KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|----------------------|--------|--------|--------|--------|
| Diluted EPS (\$, mm) | 25.13 | 22.96 | 24.28 | 27.57 |
| Organic Growth (%) | 16.9 | (3.5) | 3.0 | 8.0 |
| Adj EBITDA (\$, mm) | 12,969 | 11,926 | 12,377 | 13,928 |

INVESTMENT DRIVERS

- A focused expansion into high growth end markets and geographies
- Broad product/service menu, coupled with scale drives best-in class resilience in the business model
- Operating margin expansion via price/volume and benefits of scale

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS



Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Greater than expected tailwind / lower than expected headwind from COVID-19 pandemic
- Improved macroeconomic conditions could influence spending of customers

RISKS TO DOWNSIDE

- Lower than expected tailwind / greater than expected headwind from COVID-19 pandemic
- As a global company, a downturn in political climate and regional conditions could adversely impact operations in those regions

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 67.7% | |
| HF Sector Long/Short Ratio | 2.2x | |
| HF Sector Net Exposure | 20.5% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2022e

| | | | |
|-----------------------------|--------|--|--------|
| Sales / Revenue (\$, mm) | 42,973 | | 43,155 |
| | | | 43,249 |

| | | | |
|--------------------|--------|--|--------|
| EBITDA (\$, mm) | 11,585 | | 11,926 |
| | | | 11,905 |

| | | | |
|-------------|-------|--|-------|
| EPS (\$) | 22.84 | | 22.96 |
| | | | 23.00 |

◆ Mean ◆ Morgan Stanley Estimates
Source: Refinitiv, Morgan Stanley Research


Risk Reward – Visa Inc. (V.N)

Resilient double-digit returns over the medium term offers appealing risk reward

PRICE TARGET \$291.00

Based on 33.0x target P/E multiple on our base-case CY23 EPS estimate. This target multiple is 1.5x premium to the V's 3-year average multiple given more growth opportunities and a 2x discount to our valuation for Mastercard given slower medium-term growth at V off a large base.

Consensus Price Target Distribution



RISK REWARD CHART



BULL CASE

35x CY23e bull-case EPS

Upside from new initiatives and growth channels combined with organic payment volume growth drives a high-teens revenue CAGR in 2021-24, accompanied by a low-20% annual EPS growth.

\$336.00

BASE CASE

33x CY23e base-case EPS


Organic payment volume recovery continues as spending recovers from COVID-19 related impacts and international tourism climbs back. Net revenues grow at a mid-teens CAGR in 2021-24, with the fastest growth in 2022 as travel and domestic spending continue to recover. Adj. EPS grows high-teens on scale and buybacks.

\$291.00

OVERWEIGHT THESIS

V is one of our preferred stocks, as it is a key beneficiary of resilient global consumer spend growth, the ongoing shift from cash to electronic payments, and broadening merchant acceptance. Global Personal Consumption Expenditure and secular growth drivers should support low double-digit revenue growth in the near-to-medium term. We see upside opportunity from faster-than expected recovery of travel and the sustained strength of cross-border ecommerce. Continued investment in longer term initiatives (faster payments, P2P, B2B) and partnerships continue to increase its TAM and offer an opportunity for compounding double digit earnings growth for the foreseeable future.

Consensus Rating Distribution



Risk Reward Themes

Pricing Power: *Positive*
Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BEAR CASE

\$189.00

23x CY23e bear-case EPS

Organic payment volume growth slows as Covid-19 impacts worsen and international tourism remains weak, resulting in a low-teens revenue growth CAGR in 2021-24, while Adj. EPS grows mid-teens as V invests to defend its position.

Risk Reward – Visa Inc. (V.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-------------------------------------|------|-------|-------|-------|
| US Payment Volume YoY Growth (%) | 21.2 | 15.0 | 10.2 | 7.2 |
| Total Payment Volume YoY Growth (%) | 18.1 | 12.4 | 9.5 | 8.6 |
| Total Revenue YoY Growth (%) | 10.3 | 20.6 | 13.1 | 11.3 |
| Adj. Operating Margin (%) | 66.5 | 67.9 | 68.4 | 69.7 |
| Adj. EPS Growth (%) | 17.4 | 25.5 | 14.1 | 15.1 |


CATALYST CALENDAR

| Date | Event | Source: Refinitiv, Morgan Stanley |
|---------------------------|--------------------------------------|-----------------------------------|
| 25 Jan 2023 - 29 Jan 2023 | Visa Inc Annual Shareholders Meeting | |

INVESTMENT DRIVERS

- Growth in global personal consumer expenditure
- Shift of consumer payments from cash to card
- Market share gains from key competitors and local schemes
- Adoption/monetization of B2B offerings
- Regulatory environment

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 3/5 BEST | 24 Month Horizon | 2/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

SUSTAINABILITY & ESG

| | | | |
|---------------------|------|------|------|
| Indicator of Change | 0.58 | +1.0 | -1.0 |
| Disclosure Rate | 57% | | |

MS ESTIMATES VS. CONSENSUS

FY Sep 2023e

| | | |
|-----------------------------|--------|--------|
| Sales / Revenue (\$, mm) | 30,306 | 32,862 |
| | 32,441 | |

| | | |
|------------------|--------|--------|
| EBIT (\$, mm) | 20,261 | 22,472 |
| | 22,122 | |

| | | |
|-------------|------|------|
| EPS (\$) | 7.67 | 8.47 |
| | 8.42 | |

◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

RISKS TO PT/RATING

RISKS TO UPSIDE

- Faster than expected recovery of cross-border tourism
- Ability to continue to meet/beat expectations
- Faster-than-expected adoption/scaling of B2B solutions, driving multiple expansion

RISKS TO DOWNSIDE

- Material slowdown in consumer spend; Further slowdown in cross-border growth
- Portfolio losses in the US
- Regulatory changes in key markets promoting domestic schemes

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|-----------------------------------|
| Inst. Owners, % Active | 66.4% | <div style="width: 66.4%;"></div> |
| HF Sector Long/Short Ratio | 2.2x | <div style="width: 2.2x%;"></div> |
| HF Sector Net Exposure | 32.9% | <div style="width: 32.9%;"></div> |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure – Short Exposure).

Risk Reward – Zoetis Inc. (ZTS.N)

Top Pick

Compelling Advantages in Leadership Positioning and Innovation

PRICE TARGET \$264.00


46x base case 2023E EPS. Our target multiple is at a premium to its Animal Health peers (26x), which we believe is warranted given its leadership positioning, innovation catalysts, margin expansion, and capital deployment optionality. Our PT is also based on our Discounted Cash Flow Analysis that uses a WACC of 4% and a 2% terminal growth rate.

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)



Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target


Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 23 Aug, 2022. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

| BULL CASE | \$310.00 | BASE CASE | \$264.00 | BEAR CASE | \$168.00 |
|---|----------|--|----------|--|----------|
| 51x bull case 2023E EPS | | 46x base case 2023E EPS | | 32x bear case 2023E EPS | |
| Revenue and earnings results exceed expectations, new products gain meaningful traction, and capital deployment activity offers upside. Strong sales growth and accelerated market share gains from Simparica Trio and novel monoclonal antibodies for pain exceed expectations. Organic EPS upside of 5% plus M&A upside of 3% yields EPS 8% above forecast. | | ZTS will continue to benefit from robust Animal Health fundamentals as an industry leader and innovation. We expect growing traction for new products and ancillary offerings with best-in-class commercialization execution, supporting +HSD topline growth, which along with 100 bps of operating margin expansion annually on increasingly favorable species/product mix and continuing operational efficiency initiatives, will drive +DD earnings growth. | | Traction for new products and overall financial results fall short of expectations. ZTS faces greater than expected competitive pressures and product launch challenges across parasiticides, atopic dermatitis, and new pain monoclonal antibodies. Company misses EPS estimate by 8% and the P/E multiple contracts. | |

OVERWEIGHT THESIS

- Powerful structural tailwinds across animal health should support demand for ZTS's products and services as the industry leader.
- Company-specific drivers in innovation and expanding exposure to faster-growing categories (companion animal and diagnostics) will support above-market topline growth and double-digit earnings growth.
- Faster growth, positive new product developments, and tuck-in M&A potential yield Bull Case upside. Financial shortfalls, competitive pressures and new product disappointments yield Bear Case downside.

Consensus Rating Distribution



● MS Rating

Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

| | |
|-----------------|----------|
| Secular Growth: | Positive |
| Market Share: | Positive |

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – Zoetis Inc. (ZTS.N)

KEY EARNINGS INPUTS

| Drivers | 2021 | 2022e | 2023e | 2024e |
|-------------------------|------|-------|-------|-------|
| Net revenues growth (%) | 16.5 | 6.4 | 9.0 | 7.7 |
| Gross profit growth (%) | 18.1 | 6.5 | 9.6 | 8.3 |
| EBITDA growth (%) | 18.6 | 7.2 | 12.5 | 9.1 |


CATALYST CALENDAR

| Date | Event | Source: Refinitiv, Morgan Stanley |
|---------------------------|--|-----------------------------------|
| 30 Jun 2022 - 31 Dec 2022 | Launch Librela in the US | |
| H2 2022 | Launch Solensia in the US (US FDA Approval as of mid-Jan.) | |

INVESTMENT DRIVERS

- Quarterly results and guidance updates
- Global animal health demand dynamics
- Pipeline developments
- Capital Deployment

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

| | | | |
|-------------|---------------------|-------------|--------------------|
| 3/5 BEST | 24 Month Horizon | 5/5 MOST | 3 Month Horizon |
|-------------|---------------------|-------------|--------------------|

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Meaningful upside from quarterly results/guidance updates
- Better than expected traction for market-leading growth franchises (Apoquel, Cytopoint, Simparica Trio, upcoming monoclonal antibodies for pain) remain unchallenged
- Capital deployment/M&A

RISKS TO DOWNSIDE

- Sales/earnings shortfalls
- Competitive threats to key products
- Unexpected deterioration in pet spending
- Unfavorable regulatory dynamics across livestock

OWNERSHIP POSITIONING

| | | |
|----------------------------|-------|--|
| Inst. Owners, % Active | 64.4% | |
| HF Sector Long/Short Ratio | 2.2x | |
| HF Sector Net Exposure | 20.5% | |

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Dec 2023e

| | | | |
|-----------------------------|-------|--|-------|
| Sales / Revenue (\$, mm) | 8,646 | | 9,021 |
| | | | 8,946 |

| | | | |
|--------------------|-------|--|-------|
| EBITDA (\$, mm) | 3,526 | | 3,912 |
| | | | 3,853 |

| | | | |
|------------------------|-------|--|-------|
| Net income (\$, mm) | 2,524 | | 2,715 |
| | | | 2,645 |

| | | | |
|-------------|------|--|------|
| EPS (\$) | 5.41 | | 5.78 |
| | | | 5.66 |

♦ Mean ♦ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Disclaimers

Morgan Stanley is acting as financial advisor to 1Life Healthcare, Inc. ("One Medical") in connection with its definitive merger agreement to be acquired by Amazon.com, Inc., as announced on July 21, 2022. The proposed transaction is subject to satisfying customary closing conditions, including approval by One Medical's shareholders and regulatory approval. This report and the information provided herein is not intended to (i) provide voting advice, (ii) serve as an endorsement of the proposed transaction, or (iii) result in the procurement, withholding or revocation of a proxy or any other action by a security holder. One Medical has agreed to pay fees to Morgan Stanley for its financial services, including transaction fees that are contingent upon the consummation of the transaction. Please refer to the notes at the end of the report.

Disclosure Section

Mortgage Backed Securities (MBS) and Collateralized Mortgage Obligations (CMO)

Principal is returned on a monthly basis over the life of the security. Principal prepayment can significantly affect the monthly income stream and the maturity of any type of MBS, including standard MBS, CMOs and Lottery Bonds. Yields and average lives are estimated based on prepayment assumptions and are subject to change based on actual prepayment of the mortgages in the underlying pools. The level of predictability of an MBS/CMO's average life, and its market price, depends on the type of MBS/CMO class purchased and interest rate movements. In general, as interest rates fall, prepayment speeds are likely to increase, thus shortening the MBS/CMO's average life and likely causing its market price to rise. Conversely, as interest rates rise, prepayment speeds are likely to decrease, thus lengthening average life and likely causing the MBS/CMO's market price to fall. Some MBS/CMOs may have "original issue discount" (OID). OID occurs if the MBS/CMO's original issue price is below its stated redemption price at maturity, and results in "imputed interest" that must be reported annually for tax purposes, resulting in a tax liability even though interest was not received. Investors are urged to consult their tax advisors for more information. Government agency backing applies only to the face value of the CMO and not to any premium paid.

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Michael J. Cyprys, CFA, CPA; Diane Ding, Ph.D.; James E Fauchette; Terence C Flynn, Ph.D.; Hamza Fodderwala; Betsy L. Graseck, CFA; Richard Hill; Adam Jonas, CFA; Kristine T Liwag; Devin McDermott; Dara Mohsenian, CFA; Brian Nowak, CFA; Andrew B Pauker; Tejas Savant; Benjamin Swinburne, CFA; Michelle M. Weaver, CFA; Michael J Wilson; Erik W Woodring; Erin Wright.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

The analyst or strategist (or a household member) identified below owns the following securities (or related derivatives): Diane Ding, Ph.D. - Simon Property Group Inc(common or preferred stock), Visa Inc.(common or preferred stock); James E Fauchette - Amazon.com Inc(common or preferred stock); Terence C Flynn, Ph.D. - Amazon.com Inc(common or preferred stock), Exxon Mobil Corporation(common or preferred stock), Monster Beverage Corp(common or preferred stock), Visa Inc.(common or preferred stock); Hamza Fodderwala - Exxon Mobil Corporation(common or preferred stock); Betsy L. Graseck, CFA - Amazon.com Inc(common or preferred stock), Exxon Mobil Corporation(common or preferred stock), Visa Inc.(common or preferred stock); Adam Jonas, CFA - Amazon.com Inc(common or preferred stock); Brian Nowak, CFA - Exxon Mobil Corporation(common or preferred stock), Simon Property Group Inc(common or preferred stock), Wells Fargo & Co.(common or preferred stock); Erik W Woodring - Amazon.com Inc(common or preferred stock).

As of July 29, 2022, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Amazon.com Inc, CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Exxon Mobil Corporation, Ferrari NV, Lockheed Martin Corp, Monster Beverage Corp, Palo Alto Networks Inc, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co., Zoetis Inc..

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Lockheed Martin Corp, State Street Corporation, Thermo Fisher Scientific Inc., Wells Fargo & Co..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Ferrari NV, Lockheed Martin Corp, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Wells Fargo & Co..

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Exxon Mobil Corporation, Ferrari NV, Lockheed Martin Corp, Monster Beverage Corp, Palo Alto Networks Inc, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Exxon Mobil Corporation, Ferrari NV, Lockheed Martin Corp, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co., Zoetis Inc..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Exxon Mobil Corporation, Ferrari NV, Lockheed Martin Corp, Monster Beverage Corp, Palo Alto Networks Inc, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Amazon.com Inc, CBOE Global Markets Inc., CDW Corporation, Eli Lilly & Co., Endeavor Group Holdings, Inc, Exxon Mobil Corporation, Ferrari NV, Lockheed Martin Corp, Palo Alto Networks Inc, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co., Zoetis Inc..

Morgan Stanley & Co. LLC makes a market in the securities of Amazon.com Inc, CDW Corporation, Eli Lilly & Co., Exxon Mobil Corporation, Lockheed Martin Corp, Monster Beverage Corp, Palo Alto Networks Inc, Simon Property Group Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa Inc., Wells Fargo & Co., Zoetis Inc..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing

liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of July 31, 2022)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

| STOCK RATING CATEGORY | COVERAGE UNIVERSE | | INVESTMENT BANKING CLIENTS (IBC) | | | OTHER MATERIAL INVESTMENT SERVICES CLIENTS (MISC) | |
|--------------------------|-------------------|---------------|----------------------------------|-------------------|----------------------------|---|--------------------------------|
| | COUNT | % OF TOTAL | COUNT | % OF TOTAL IBC | % OF RATING CATEGORY | COUNT | % OF TOTAL OTHER MISC |
| | | | | | | | |
| Overweight/Buy | 1366 | 39% | 318 | 42% | 23% | 593 | 39% |
| Equal-weight/Hold | 1559 | 44% | 357 | 47% | 23% | 708 | 46% |
| Not-Rated/Hold | 0 | 0% | 0 | 0% | 0% | 0 | 0% |
| Underweight/Sell | 613 | 17% | 91 | 12% | 15% | 226 | 15% |
| TOTAL | 3,538 | | 766 | | | 1527 | |

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC & E*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of Amazon.com Inc, CBOE Global Markets Inc., Eli Lilly & Co., Exxon Mobil Corporation, Lockheed Martin Corp, Palo Alto Networks Inc, State Street Corporation, Thermo Fisher Scientific Inc., Visa

Inc., Wells Fargo & Co., Zoetis Inc..

As of August 24, 2022, State Street Corporation beneficially owned 5% or more of a class of common equity securities of Morgan Stanley.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters

arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118J); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

Morgan Stanley Bank AG currently acts as a designated sponsor for the following securities: CBOE Global Markets Inc..

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DFIC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

© 2022 Morgan Stanley